CurrentUnitedHealthcarePolicy N/A

Medical Policy Update Bulletin Quick View : March 2026

A bulletin listing recently added, updated, revised, replaced, and retired UnitedHealthcare Medical Policies and Medical Benefit Drug Policies with effective dates; serves as an index/summary pointing to full policy documents and states general guidance about coverage determination according to member benefit plans.

Policy Summary

PayerUnitedHealthcare

PolicyMedical Policy Update Bulletin Quick View : March 2026

Policy CodePolicy N/A

Change TypeMultiple revisions and updates

Effective DateApr 1, 2026

Next Review DateN/A

Key ActionProviders must determine coverage based on the member's benefit plan and applicable federal/state law; obtain written member consent before billing for services not covered.

SourceLink

POLICY UPDATE CHANGES

Preventive Care Services policy revised, effective Apr. 1, 2026.

Spinal Fusion and Decompression policy revised, effective Apr. 1, 2026.

Treatment of Temporomandibular Joint Disorders policy revised, effective Mar. 1, 2026.

Vertebral Body Tethering for Scoliosis policy revised, effective Apr. 1, 2026.

Category III Codes status updated, effective Apr. 1, 2026.

Embolization of the Ovarian and Iliac Veins for Pelvic Congestion Syndrome status updated, effective Mar. 1, 2026.

Lower Extremity Endovascular Procedures updated effective Mar. 1, 2026 and revised effective May 1, 2026.

Surgery of the Hip policy updated, effective Mar. 1, 2026.

Surgery of the Knee policy updated, effective Mar. 1, 2026.

Complement C5 Inhibitors drug policy revised, effective Apr. 1, 2026.

Denosumab drug policy revised, effective Apr. 1, 2026.

Evkeeza (Evinacumab-Dgnb) drug policy updated, effective Apr. 1, 2026.

FcRn Blockers drug policy revised, effective Apr. 1, 2026.

Oncology Medication Clinical Coverage policy revised, effective Apr. 1, 2026.

Ophthalmologic VEGF Inhibitors drug policy revised, effective Apr. 1, 2026.

Provider Administered Drugs - Site of Care policy revised, effective Apr. 1, 2026.

Respiratory Interleukins (Cinqair, Fasenra, & Nucala) updated, effective Apr. 1, 2026.

Somatostatin Analogs drug policy revised, effective Apr. 1, 2026.

Uplizna (Inebilizumab-Cdon) drug policy revised, effective Apr. 1, 2026.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Bulletin Summary

This bulletin is an index of recent policy changes across UnitedHealthcare/UMR medical and medical benefit drug policies, summarizing newly added, updated, revised, replaced, and retired policies and their effective dates. Inclusion indicates adoption or management change but does not equate to coverage; coverage must be determined by the member's benefit plan and applicable law.

Coverage stance: informational. Payer: UnitedHealthcare. Bulletin: March 2026.

Key facts

Effective dateApr 1, 2026

StatusCURRENT

SubjectUnitedHealthcare Medical Policy Update Bulletin - March 2026

Key ActionRefer to full policies for coverage & PA requirements

Policies listed as New/Updated/Revised/Retired20+

Most drug policy effective dateApr 1, 2026

Common effective date for several surgical policiesMar 1, 2026

Index of Policy Changes

The following section lists each policy entry from the bulletin and the associated effective dates; each entry also notes whether the change is material (the bulletin includes is_material flags). Inclusion in this list is informational and does not imply UnitedHealthcare covers the service.

Policy Name	Change Type	Effective Date
Preventive Care Services	Revised	Effective Apr. 1, 2026
Spinal Fusion and Decompression	Revised	Effective Apr. 1, 2026
Treatment of Temporomandibular Joint Disorders	Revised	Effective Mar. 1, 2026
Vertebral Body Tethering for Scoliosis	Revised	Effective Apr. 1, 2026
Category III Codes	Updated	Effective Apr. 1, 2026
Embolization of the Ovarian and Iliac Veins for Pelvic Congestion Syndrome	Updated	Effective Mar. 1, 2026
Lower Extremity Endovascular Procedures	Updated	Updated effective Mar. 1, 2026; Revised effective May 1, 2026
Surgery of the Hip	Updated	Effective Mar. 1, 2026
Surgery of the Knee	Updated	Effective Mar. 1, 2026
Complement C5 Inhibitors	Revised	Effective Apr. 1, 2026
Denosumab	Revised	Effective Apr. 1, 2026
Evkeeza (Evinacumab-Dgnb)	Updated	Effective Apr. 1, 2026
FcRn Blockers	Revised	Effective Apr. 1, 2026
Oncology Medication Clinical Coverage	Revised	Effective Apr. 1, 2026
Ophthalmologic VEGF Inhibitors	Revised	Effective Apr. 1, 2026
Provider Administered Drugs - Site of Care	Revised	Effective Apr. 1, 2026
Respiratory Interleukins (Cinqair, Fasenra, & Nucala)	Updated	Effective Apr. 1, 2026
Somatostatin Analogs	Revised	Effective Apr. 1, 2026
Uplizna (Inebilizumab-Cdon)	Revised	Effective Apr. 1, 2026

What Providers Must Do

Documentation Required

Refer to individual policies for coverage determinations

Providers must determine coverage based on the member's benefit plan and applicable federal/state law; the bulletin is informational and does not itself imply coverage. Obtain written member consent before billing members for services not covered by the benefit plan.

Prior Authorization

Policy-specific prior authorization may apply

New, revised, or updated policies may introduce or change prior authorization requirements — providers should consult the full, specific Medical Policy or Medical Benefit Drug Policy at UHCprovider.com/policies for PA and clinical criteria.

Providers should consult the full Medical Policy or Medical Benefit Drug Policy at UHCprovider.com/policies for details on prior authorization, clinical criteria, billing, and member liability; inclusion in the bulletin does not mean UnitedHealthcare covers the service.

Change Type Definitions

Definitions used in the bulletin:

Term	Definition
New	New clinical coverage criteria have been adopted for a health service.
Updated	An existing policy has been reviewed and changes have not been made to the clinical coverage criteria; however, items such as the clinical evidence, FDA information, and/or list(s) of applicable codes may have been updated
Revised	An existing policy has been reviewed and revisions have been made to the clinical coverage criteria
Replaced	An existing policy has been replaced with a new or different policy
Retired	The health service(s) addressed in the policy are no longer being managed or are considered to be proven/medically necessary and are therefore not excluded as unproven/not medically necessary services, unless coverage guidelines or criteria are otherwise documented in another policy

Effective Dates & Review

Document dates

Effective DateApr 1, 2026

Last Review

Next Review

Note - Most common effective datesMost drug policy effective date: Apr 1, 2026; Common effective date for several surgical policies: Mar 1, 2026

Individual policies listed may have different effective dates; providers should verify the effective date on each policy page before relying on the change for clinical or administrative decisions.

Bulletin Change Log

2026-03-01policy_changes

Treatment of Temporomandibular Joint Disorders revised; Embolization of the Ovarian and Iliac Veins for Pelvic Congestion Syndrome updated; Lower Extremity Endovascular Procedures updated (Mar. 1, 2026); Surgery of the Hip updated; Surgery of the Knee updated.

2026-04-01policy_changesLatest

Preventive Care Services revised; Spinal Fusion and Decompression revised; Vertebral Body Tethering for Scoliosis revised; Category III Codes status updated; Complement C5 Inhibitors revised; Denosumab revised; Evkeeza (Evinacumab‑Dgnb) updated; FcRn Blockers revised; Oncology Medication Clinical Coverage revised; Ophthalmologic VEGF Inhibitors revised; Provider Administered Drugs - Site of Care revised; Respiratory Interleukins (Cinqair, Fasenra, & Nucala) updated; Somatostatin Analogs revised; Uplizna (Inebilizumab‑Cdon) revised.